赛托生物(300583) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was ¥222,171,115.42, a decrease of 22.68% compared to ¥287,321,415.48 in the same period last year[8] - Net profit attributable to shareholders was -¥24,243,112.96, representing a decline of 175.65% from ¥32,045,197.48 year-on-year[8] - Basic earnings per share decreased to -¥0.2249, down 174.87% from ¥0.3004 in the same period last year[8] - The company's operating revenue for Q1 2020 was RMB 222,171,115.42, a decrease of 22.68% compared to RMB 287,321,415.48 in Q1 2019[25] - The net profit attributable to shareholders was -¥2,424.31 million, a decrease of 175.65% year-on-year, largely due to the impact of COVID-19 on market demand and production resumption[27] - The company reported a net profit for Q1 2020 of a loss of CNY 29,553,800.45, compared to a profit of CNY 31,909,160.06 in Q1 2019, representing a significant decline[50] - The company's operating profit for Q1 2020 was a loss of CNY 28,274,348.25, compared to a profit of CNY 37,751,064.54 in the previous year[49] Cash Flow - The net cash flow from operating activities improved to ¥7,804,016.99, a significant increase of 110.78% compared to -¥72,372,553.44 in the previous year[8] - The net cash flow from operating activities increased by 110.78% year-on-year, reaching ¥7,804,016.99, primarily due to reduced raw material procurement and a shift to bank acceptance bills[27] - The net cash flow from investing activities decreased by 346.51% year-on-year, amounting to -¥89,946,490.16, mainly due to increased investments in bank wealth management products[27] - The net cash flow from financing activities grew by 110.55% year-on-year to ¥22,487,003.46, driven by increased bank loans to supplement working capital[27] - Cash inflow from operating activities totaled CNY 163,102,464.55, down from CNY 184,163,186.63 year-over-year, representing a decrease of approximately 11%[56] - The net cash flow from investing activities was negative at CNY -89,946,490.16, contrasting with a positive CNY 36,488,030.24 in the same period last year[58] - The net cash flow from financing activities was CNY 22,487,003.46, compared to CNY 10,680,332.54 in the previous year, reflecting a growth of about 110%[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,911,972,514.39, a decrease of 2.52% from ¥2,987,259,062.48 at the end of the previous year[8] - Total liabilities decreased by 4.19% to RMB 1,054,376,001.75 from RMB 1,100,498,882.82[24] - Total current assets decreased from CNY 1,506,704,686.33 to CNY 1,420,501,904.10, a decline of approximately 5.73%[40] - Total current liabilities were CNY 943,052,609.30, while total liabilities stood at CNY 1,100,498,882.82[64] - Total equity decreased from CNY 1,886,760,179.66 to CNY 1,857,596,512.64, a decline of about 1.54%[43] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,317[12] - The largest shareholder, Shandong Runxin Investment Co., Ltd., held 36.93% of the shares, totaling 39,802,720 shares[12] Operational Changes and Future Plans - The company plans to continue expanding its market presence and product offerings in response to the challenges posed by the pandemic[19] - The company has decided to terminate the projects for producing 120 tons of 4-androstenedione and 180 tons of hydroxyprogesterone due to significant changes in market prices and demand[34] - The company has prioritized the production line construction and qualification application for key products while extending the construction period for non-key products[34] - The company plans to extend the project construction period by two years, with completion now expected by May 1, 2022[34] Regulatory and Compliance - The company has not reported any violations regarding external guarantees during the reporting period[36] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[37] - The company has implemented new revenue recognition and leasing standards effective January 1, 2020, impacting financial reporting[71] - The Q1 2020 report was not audited, indicating preliminary financial results[71]